ArticleMolecular biology reports2026
Intraperitoneal clodronate liposomes remodel the local macrophage niche and potentiate biomaterial-induced osteoinduction.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoinductive biomaterials hold promise for repairing critical-size bone defects, yet the mechanisms underlying materials-instructed osteoinduction (MIOI) remain unclear. Macrophages are central, and local liposomal clodronate (LipClod) typically suppresses osteogenesis. Whether systemic LipClod modulates MIOI is unknown. We investigated the effect of intraperitoneal (i.p.) LipClod on ectopic osteoinduction.
methodsMale FVB mice received subcutaneous β-tricalcium phosphate (TCPs) scaffolds and a single i.p. LipClod dose 1 day after implantation; vehicle liposomes served as controls (n = 5 per group; 10 µL/g). Recombinant macrophage colony-stimulating factor (M-CSF; 0.5–2 µg/mL; 100 µL per pocket) was injected locally, with contralateral pockets receiving PBS. Outcomes were assessed by histology, immunohistochemistry, RT-qPCR, flow cytometry.
resultsIntraperitoneal LipClod paradoxically enhanced TCPs-induced ectopic osteogenesis at 8 weeks. Following i.p. LipClod administration, the number of circulating monocytes in peripheral blood was increased. Concurrently, expansion of the monocyte–macrophage population at the implantation site was observed, accompanied by increased recruitment of mesenchymal stem cells (MSCs). In addition, local application of M-CSF further enhanced macrophage infiltration and significantly augmented osteogenesis.
conclusionsCollectively, these findings demonstrate that i.p. LipClod alters the osteogenic outcome of TCPs-induced ectopic bone formation. Systemic immune modulation is associated with changes in monocyte–macrophage dynamics and mesenchymal stem cell recruitment at the implantation site. These observations underscore the importance of immune regulation in materials-instructed osteoinduction and suggest that immune-targeted strategies may be considered to enhance the performance of osteoinductive biomaterials.
Indexed as
Identifiers
41661415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.